Results 121 to 130 of about 176,389 (357)

NAFLD in normal weight individuals [PDF]

, 2022
Nonalcoholic fatty liver disease (NAFLD) can develop in lean individuals. Despite a better metabolic profile, the risk of disease progression to hepatic inflammation, fibrosis, and decompensated cirrhosis in the lean is similar to that in obesity-related
Gerhard, Glenn S., DiStefano, Johanna K.
core   +1 more source

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Nichtalkoholische Fettlebererkrankung (NAFLD)

, 2017
Zusammenfassung. Die nichtalkoholische Fettlebererkrankung ist in den westlichen Industriestaaten die häufigste Ursache einer Hepatopathie und die Tendenz ist steigend. Grund dafür ist u. a.
Jean-François Dufour, Rauh, Christina, Dufour, Jean-François, Christina Rauh   +3 more
core   +1 more source

Characteristics of the study population (non-NAFLD vs NAFLD).

, 2023
Characteristics of the study population (non-NAFLD vs NAFLD).
Jung-Eun Oh (16612224), Nam Hun Heo (9047670), Hyun Joe (16612221), Yong-Jin Cho (5461211), Jangwon Choi (16612218), Hwang-Sik Shin (16612227)   +5 more
core   +1 more source

ER‐Localized Deadenylase PNLDC1 Suppresses Colorectal Cancer Progression by Targeting the mRNA Decay of TUBB4B

Exploration, EarlyView.
The deficiency of PNLDC1 exacerbates the advancement of CRC. PNLDC1 interacts with TUBB4B mRNA to regulate the p53–p21–CDK2–cyclin E2 pathway, thereby influencing the G2/M phase of the cell cycle. ABSTRACT Colorectal cancer (CRC) remains a leading cause of cancer‐related mortality, highlighting the urgent need for novel therapeutic strategies.
Lexin Liu, Yuelin Guan, Yuzhou Qin, Guiping Chen, Guozhen Wang, Xiang Yan, Xue Li, Lei Sun, Wei Yu, Shi Ouyang, Zhichao Ma, Zihao Xu, Zhongkai Cao, Fan Yu, Tong Zhou, Ziyou Luo, Xiangjun Chen, Yongbin Yan, Lidan Hu   +18 more
wiley   +1 more source

Association Between High Sensitivity Cardiac Troponin and All-Cause and Cardiovascular Mortality in Adults at Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study

Global Heart
Objective: Cardiovascular disease (CVD) is the leading cause of death among patients with non-alcoholic fatty liver disease (NAFLD). This study investigates the association between high-sensitivity cardiac troponin (hs-cTn) levels and mortality in adults
Enfa Zhao, Hang Xie, Yuan Gao, Xiaolin Wen, Bingtian Dong, Chaoxue Zhang   +5 more
doaj   +1 more source

Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis [PDF]

Clinical and Molecular Hepatology
Background/Aims The Fibrosis-4 index (FIB-4) is a noninvasive test widely used to rule out advanced liver fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD).
Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun   +10 more
doaj   +1 more source

Role of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3

Exploration of Medicine, 2020
Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver chronic disease worldwide. The pathogenesis of NAFLD is complex and involves many metabolic enzymes and multiple pathways.
Fatiha Nassir
doaj   +1 more source

The treatment of NAFLD.

European review for medical and pharmacological sciences, 2005
Nonalcoholic fatty liver disease (NAFLD) is becoming an increasing cause of chronic liver damage. The decision of start a medical treatment is based on the documented risk of progression to cirrhosis and liver cancer, when steatohepatitis (NASH) occurs.
TRAPPOLIERE M., TUCCILLO C., FEDERICO, Alessandro, DI LEVA A., NIOSI M., DALESSIO C., CAPASSO R., COPPOLA F., DAURIA M., LOGUERCIO, Carmelina   +9 more
openaire   +2 more sources

Nutrition and Metabolic Diseases: A Systematic Review of Functional Foods, Medicinal Plants, Phytochemicals, Bioactive Compounds and Nutrients Effective Against Metabolic Diseases

Food Chemistry International, EarlyView.
The study demonstrates how functional foods, medicinal plants, phytochemicals, bioactive compounds and essential nutrients combat metabolic diseases. It highlights their mechanisms, including antioxidant, anti‐inflammatory, insulin‐sensitising, lipid‐regulating, gut microbiota‐modulating and mitochondrial‐enhancing effects, leading to improved ...
Chinaza Godswill Awuchi, Sana Noreen, Sonia Morya   +2 more
wiley   +1 more source